Sensitive

Lewy body disease

APOE · rs429358

Where this position leads

Condition: Alzheimer's Disease Risk (APOE)

Drug: Lecanemab and other anti-amyloid antibodies

rs429358 Condition: Alzheimer's Disease Risk (APOE) Alzheimer's Disease Risk (APOE) Condition Drug: Lecanemab and other anti-amyloid antibodies Lecanemab and other anti-amyloid an… Drug Topic: Heart and circulation Heart and circulation Topic Topic: Brain and memory Brain and memory Topic Topic: Cholesterol and blood fats Cholesterol and blood fats Topic rs429358 rs429358 APOE

Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.

What each result means

C/C Published research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Lewy body disease compared to the general population.
C/T Published research associates this genotype (one copy of the reported risk allele) with an intermediate association with Lewy body disease.
T/T Published research associates this genotype with typical/baseline likelihood of Lewy body disease — no copies of the reported risk allele.
This is one of the two positions that together define the APOE e2/e3/e4 types — the other is rs7412. On its own it reports the association above. Read as a pair with rs7412 it becomes APOE genotype, which is the strongest common genetic influence on late-onset Alzheimer disease, and MyGeneLog reports that pairing on its own page: see Alzheimer’s Disease Risk (APOE). A result here is half of a two-letter answer, and half an answer is the one thing worth knowing before acting on it.
Source

What people read about alongside this

Papers in Europe PMC whose title or abstract names both this rsID and that subject. A shared paper means somebody wrote about the two together — it is not a claim that this position explains the subject.

Questions about rs429358

What is rs429358?

rs429358 is a single position in the genome, in or near the APOE gene. Published research associates it with lewy body disease. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

What conditions is rs429358 linked to?

On MyGeneLog this position is linked to Alzheimer's Disease Risk (APOE). The research behind each link, and its sources, are set out on that condition page.

Does rs429358 affect how medicines work?

APOE carries pharmacogenomic findings for Lecanemab and other anti-amyloid antibodies. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.

What do people read about alongside rs429358?

Subjects that appear in the title or abstract of the same papers as this rsID include heart and circulation (32 papers), brain and memory (29 papers), cholesterol and blood fats (27 papers), blood sugar and insulin (23 papers), learning and focus (16 papers). A shared paper means somebody wrote about the two together; it is not a claim that this position explains the topic.

Does having rs429358 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs429358 come from?

GWAS Catalog, PLoS Genet 2014, PMID:25188341. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

← See all variants